Connect Biopharma Holdings Ltd
A clinical-stage biopharma developing therapies for T cell-driven inflammatory diseases.
CNTB | US
Overview
Corporate Details
- ISIN(s):
- US2075231017
- LEI:
- Country:
- United States of America
- Address:
- 3580 CARMEL MOUNTAIN ROAD, SUITE 200, 92130 SAN DIEGO
- Website:
- https://www.connectbiopharm.com
- Sector:
- Manufacturing
Description
Connect Biopharma Holdings Ltd. is a global, clinical-stage biopharmaceutical company dedicated to developing therapies for T cell-driven inflammatory diseases. The company focuses on discovering and advancing next-generation immune modulators to treat chronic conditions, with a particular emphasis on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody targeting the interleukin-4 receptor alpha (IL-4Rα), which is being evaluated for its potential in treating various inflammatory diseases. The company aims to address significant unmet medical needs by advancing its pipeline of innovative therapeutics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Connect Biopharma Holdings Ltd filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Connect Biopharma Holdings Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Connect Biopharma Holdings Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
